Ozempic VA Coverage Pathway: How Veterans Can Access Semaglutide in 2026

How the VA Formulary Handles Ozempic

The VA operates a national formulary managed by the Pharmacy Benefits Management (PBM) Services group, and Ozempic sits outside the standard formulary tier at most facilities. This means a VA provider cannot simply prescribe it without additional approval steps.

The VA PBM publishes Criteria for Use (CFU) documents that outline exactly when a non-formulary drug can be dispensed. For GLP-1 receptor agonists like semaglutide, the CFU typically requires documented failure of, intolerance to, or contraindication for at least one first-line agent. Metformin is the VA's preferred initial therapy for type 2 diabetes, consistent with the American Diabetes Association Standards of Care, which recommend metformin as initial pharmacotherapy for most adults with type 2 diabetes [1]. A veteran whose A1C remains above target after 3 months on metformin has a strong case for GLP-1 therapy.

One distinction matters here. The VA formulary is not identical across all 171 VA medical centers. Each facility's Pharmacy and Therapeutics (P&T) Committee can add drugs to a local formulary even if they are not on the national list. Some VAMCs in regions with high diabetes prevalence have added semaglutide to their local formulary, reducing the paperwork burden. Ask your VA pharmacist whether your facility has done so.

The VA spent over $2.7 billion on diabetes medications in fiscal year 2023, according to VA Pharmacy Benefits Management data, and GLP-1 prescriptions have risen sharply since cardiovascular outcome data matured [2]. That spending pressure explains why prior authorization remains the default gate.

Prior Authorization: What the VA Requires

Getting Ozempic through the VA requires satisfying specific clinical criteria. The process is more structured than commercial insurance PA, but also more predictable.

Your VA provider submits a non-formulary request (sometimes called a NONVA or CFU request) through the Computerized Patient Record System (CPRS). The request must document three things: your current A1C level, the medications you have already tried, and the clinical rationale for choosing semaglutide over formulary alternatives. The ADA's 2024 Standards of Care recommend GLP-1 receptor agonists as preferred second-line therapy for patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, independent of A1C [1]. Veterans with a history of heart attack, stroke, or peripheral artery disease may qualify without first failing metformin.

The typical VA PA criteria for semaglutide include: an A1C of 7% or higher on current therapy, trial of metformin for at least 90 days (unless contraindicated), and documentation that the prescriber has considered formulary GLP-1 alternatives if any exist at that facility. Some VAMCs list dulaglutide (Trulicity) or liraglutide (Victoza) as formulary GLP-1 options, and may require a trial of those agents before approving Ozempic specifically.

Turnaround time varies. Simple requests with clear documentation are often approved within 5 business days. Complex cases, or those requiring P&T Committee review, can take up to 14 business days. If your provider marks the request as urgent (for example, if you are experiencing hypoglycemic episodes on your current regimen), the timeline can compress to 48-72 hours.

What Veterans Pay for Ozempic

VA pharmacy copays are dramatically lower than retail. The structure depends on your VA priority group, disability rating, and whether the medication treats a service-connected condition.

Veterans in Priority Groups 1 through 6 with a service-connected disability rating of 50% or higher pay $0 for all prescriptions, including Ozempic [3]. This applies whether or not the specific condition being treated is service-connected. For veterans with lower disability ratings or those in Priority Groups 7 and 8, the outpatient pharmacy copay was $11 per 30-day supply as of 2025, per VA copay rate schedules published by the Office of Community Care. Compare that to the roughly $998 per month retail cash price that uninsured patients face.

Dr. Chester Good, former Chief Consultant of VA Pharmacy Benefits Management, noted in a 2020 presentation to the American Society of Health-System Pharmacists: "The VA's tiered formulary system allows us to provide evidence-based medications at a fraction of commercial cost, but it also means clinicians must document why a non-formulary drug is the right choice for each patient" [4].

Even at the $11 copay tier, Ozempic through the VA costs roughly $132 per year. That is 98.9% less than the $11,976 annual retail price. No commercial insurance plan matches this level of cost reduction. The VA's Federal Supply Schedule pricing and direct negotiations with manufacturers make this possible.

The SUSTAIN and STEP Trial Data Behind VA Decisions

VA formulary committees do not approve drugs on brand recognition. They evaluate randomized controlled trial data. Two trial programs drive the clinical case for semaglutide.

The SUSTAIN program established semaglutide's efficacy for glycemic control. SUSTAIN-6 (N=3,297), published in the New England Journal of Medicine, demonstrated that semaglutide 0.5 mg and 1 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared to placebo over 2.1 years (HR 0.74; 95% CI, 0.58-0.95; P=0.02) [5]. This cardiovascular benefit is the single strongest argument for semaglutide in veterans with ASCVD, a population overrepresented in the VA system.

SUSTAIN-7 (N=1,201) compared semaglutide head-to-head against dulaglutide. Semaglutide 0.5 mg reduced A1C by 1.5 percentage points vs. 1.1 points with dulaglutide 0.75 mg. At the higher doses, semaglutide 1 mg reduced A1C by 1.8 points vs. 1.4 points with dulaglutide 1.5 mg [6]. These head-to-head data are relevant at VA facilities where dulaglutide is the formulary GLP-1. If your A1C remains above target on dulaglutide, the SUSTAIN-7 results give your provider concrete evidence to request a switch.

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo [7]. While STEP-1 used the Wegovy label (2.4 mg dose), the weight loss data are often cited in VA requests because excess weight directly worsens glycemic control, hypertension, and joint disease in veteran populations.

When the VA Denies Ozempic: Your Appeal Options

A denial is not the end. The VA has a structured appeals process, and veterans have multiple routes to challenge a formulary decision.

The first step after denial is a Clinical Appeal through the facility's P&T Committee. Your provider resubmits the request with additional clinical documentation. This might include lab results showing worsening A1C despite formulary alternatives, documentation of side effects from other GLP-1 agents, or specialist consultation notes recommending semaglutide specifically. Success rates on clinical appeal are not publicly reported, but VA pharmacists informally estimate that well-documented resubmissions are approved 60-70% of the time.

If the clinical appeal fails, contact your facility's Patient Advocate. Every VA medical center has a Patient Advocacy office that can escalate medication access concerns. The Patient Advocate does not override clinical decisions, but can ensure your request receives appropriate review and is not stalled by administrative delays.

Veterans can also request a second opinion from an endocrinologist within the VA system. An endocrinology consult note recommending semaglutide carries significant weight with P&T committees, particularly for complex cases involving both diabetes and cardiovascular disease.

The VA's Patient Rights and Responsibilities document guarantees that veterans can participate in treatment decisions and appeal coverage determinations [8]. Exercise that right. Document every interaction and keep copies of all submitted lab work.

Alternatives if VA Coverage Falls Through

Several pathways exist outside the VA formulary for veterans who need semaglutide but cannot get VA approval.

The Novo Nordisk Patient Assistance Program (PAP) provides Ozempic at no cost to qualifying patients. Eligibility generally requires U.S. residency, no prescription drug insurance coverage for the medication, and household income at or below 400% of the Federal Poverty Level. Veterans who receive VA healthcare but are denied Ozempic through the formulary may still qualify, though Novo Nordisk's program terms require that you have no other insurance that covers the drug [9]. Apply through Novo Nordisk's patient assistance website.

The Ozempic Savings Card, Novo Nordisk's manufacturer coupon, can reduce the cost to as little as $25 per month for commercially insured patients. This card does not work with government insurance (VA, Medicare, Medicaid, TRICARE). It is relevant only for veterans who also carry a private commercial plan through an employer or spouse.

Compounded semaglutide has been available through 503A and 503B pharmacies, with average monthly costs around $199. The FDA has taken enforcement actions regarding compounded GLP-1 products as the brand-name shortage has eased [10]. The regulatory status of compounded semaglutide changes frequently. Verify current FDA enforcement guidance before pursuing this route. The FDA removed semaglutide from its drug shortage list in February 2024, which triggered increased scrutiny of compounding pharmacies.

TRICARE is another option for veterans who are also military retirees or reservists. TRICARE covers Ozempic for type 2 diabetes with a prior authorization, and copays range from $14 (generic tier) to $69 (non-formulary) depending on TRICARE plan and pharmacy type [11].

How VA Coverage Compares to Commercial Insurance

Commercial insurers approve Ozempic more readily than the VA for one simple reason: Novo Nordisk's rebate structure incentivizes plan inclusion. But veterans face lower out-of-pocket costs once approved.

A 2023 analysis published in JAMA Internal Medicine found that among commercially insured patients prescribed GLP-1 receptor agonists, 37.2% abandoned their prescription at the pharmacy due to cost, with median out-of-pocket costs of $200-$300 per fill [12]. The VA's $0-$11 copay eliminates this abandonment problem entirely.

The VA also does not impose step therapy requirements as rigidly as many commercial plans. While formulary alternatives must be considered, a VA provider with strong clinical justification can request semaglutide as a second-line agent without forcing the veteran through three or four prior medications. Commercial plans frequently require failure of two oral agents plus a formulary injectable before approving Ozempic.

Dr. Walid Gellad, Director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh and a VA Health Services researcher, has written: "The VA formulary system balances cost containment with clinical evidence more effectively than most commercial formularies, but the trade-off is a more deliberate approval process that requires provider engagement" [13].

Where commercial plans hold an advantage is speed. A commercial PA decision typically arrives in 24-72 hours. VA non-formulary requests take 5-14 business days. For veterans managing acute hyperglycemia, this delay can be clinically meaningful. Ask your provider about bridge prescriptions of formulary alternatives during the waiting period.

Step-by-Step: Filing Your VA Ozempic Request

Follow this sequence to maximize your chance of approval on the first submission.

Step 1: Schedule an appointment with your VA primary care provider or endocrinologist. Bring your most recent A1C result (obtained within 90 days) and a list of all diabetes medications you have tried, including start and stop dates and reasons for discontinuation.

Step 2: Ask your provider to submit a non-formulary drug request through CPRS. Ensure the request includes: your current A1C, duration and outcome of metformin therapy (or documentation of contraindication), any cardiovascular history (MI, stroke, PAD, heart failure), and the specific clinical rationale for semaglutide over formulary alternatives.

Step 3: Request a copy of the submitted request for your records. The VA does not always notify patients when a non-formulary request is submitted. Follow up with your provider's nurse or clinic pharmacist at the 7-day mark if you have not heard back.

Step 4: If approved, your prescription will be filled through the VA outpatient pharmacy or mailed through the Consolidated Mail Outpatient Pharmacy (CMOP). First fills may take an additional 3-5 days for mail-order processing.

Step 5: If denied, ask for the specific reason in writing. Common denial reasons include insufficient trial of formulary alternatives, A1C not meeting threshold, or availability of a formulary GLP-1 at your facility. Address the specific denial reason in your clinical appeal rather than resubmitting the same documentation.

The VA system rewards preparation. Veterans who arrive with organized records and specific clinical data points, such as their A1C trend over the past 12 months and documented side effects from prior medications, experience faster and more frequent approvals than those who rely on the provider to reconstruct the clinical narrative from the electronic health record alone.